Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Genitourinary Cancers
•
Bladder Cancer
How would you treat a non-surgical T1 high grade urothelial carcinoma of the bladder with a remote history of prostate cancer?
Related Questions
Would you consider maintenance immunotherapy after cisplatin-gemcitabine chemotherapy and chemoRT for stage 3 bladder cancer in a patient declining cystectomy or who is a poor surgical candidate?
Is it appropriate to offer definitive trimodality therapy, as an equivalent option to neoadjuvant chemotherapy followed by radical cystectomy, in patients with muscle-invasive bladder cancer regardless of fitness or platinum eligibility?
In patients who have residual bladder tumors after maximal TURBT, would you boost the GTV above typical doses, 55 Gy/20 fractions or 64 Gy/32 fractions, assuming you can meet constraint?
Given results of BCON trial, do you add carbogen and nicotinamide for patients receiving definitive radiotherapy for bladder cancer, particularly for non-cisplatin eligible candidates?
How do you reconcile discrepancies in clinical prostate cancer staging with AJCC and NCCN?
How do you define the suprapubic volume for adjuvant penile cancer treatment?
How would you treat node positive prostate cancer with only a single peri-rectal node on PSMA PET but no other nodal basins involved?
How do you assess treatment response after prostate XRT in the setting of low volume metastatic disease?
Should rectal spacing only be considered routinely for patients who are at elevated risk of rectal toxicity?
How would you approach adjuvant systemic therapy for an isolated, oligometastatic CNS recurrence of RCC that was treated with SBRT?
